Palisades Therapeutics points to shared inflammatory mechanism across chronic diseases

Palisades Therapeutics says a new peer-reviewed Perspective in Frontiers in Pharmacology supports studying selective glucocorticoid receptor modulation as a host-directed strategy across several chronic diseases. The publication ties together clinical experience with PT150 and preclinical data on PT157, while cautioning that the work outlines a testable hypothesis, not a proven broad treatment.

Why it matters: - Palisades Therapeutics is framing inflammatory priming as a possible shared upstream driver across multiple chronic diseases, including neuropsychiatric, neurodegenerative, metabolic, post-infectious and selected cancer settings. - The company’s pitch is that selective glucocorticoid receptor modulation could complement disease-specific treatments without broadly suppressing immunity. - The publication may help define which patient groups and disease areas deserve further study.

What happened: - Pop Test Oncology LLC, dba Palisades Therapeutics, announced the publication of a peer-reviewed Perspective in Frontiers in Pharmacology on Oct. 19, 2026. - The article, titled “Glucocorticoid Receptor Modulation as a Host-Directed Strategy for Inflammatory Priming Across Chronic Disease States,” examines glucocorticoid receptor modulation as a host-directed strategy. - The Perspective is available online as a full article More information. - The work draws on research from Colorado State University, Baylor College of Medicine, the University of Kentucky, Medical University of South Carolina and the Icahn School of Medicine at Mount Sinai.

The details: - The Perspective combines evidence from molecular signaling, transcriptomics, cellular systems, animal models and early human investigations. - The authors argue that dysregulated glucocorticoid receptor signaling may be a shared upstream contributor to inflammatory priming across distinct diagnoses. - The diseases discussed include post-traumatic stress disorder, alcohol use disorder, Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, obesity, glioblastoma, pancreatic ductal adenocarcinoma and post-viral syndromes including long COVID. - The proposed biology includes HPA-axis dysregulation, altered glucocorticoid receptor signaling, microglial priming, NF-κB-associated transcription, COX-2 activity and persistent inflammatory amplification. - Richard Slayden, PhD, a Perspective co-author, said the evidence converges across seven distinct experimental platforms and supports investigating PT150 and PT157 across multiple disease states. - Slayden said the goal is to restore inflammatory balance while preserving host-defense and repair pathways. - PT150 is an orally administered clinical-stage glucocorticoid receptor modulator. - PT150 has prior human exposure, CNS penetration and clinical development history that includes Phase 2 programs in alcohol use disorder funded by the National Institutes of Health and a post-traumatic stress disorder study supported by the U.S. Department of Defense. - PT157 is a structurally related next-generation dimer with preclinical data suggesting greater potency. - PT157 showed an approximately twofold mean molar potency advantage across measured endpoints. - Transcriptomic and protein-signaling studies on PT157 identified overlapping stress, inflammatory, metabolic and survival networks.

Between the lines: - The publication is building a platform story around one biological axis instead of one disease. - That approach can broaden the commercial and research relevance of PT150 and PT157, but the article itself says the framework is a testable hypothesis, not proof that one drug can treat all of the listed diseases. - The emphasis on selective modulation signals an attempt to avoid the drawbacks of broad immune suppression.

What's next: - Palisades Therapeutics says it will use the framework to guide further investigation of PT150 and PT157 across disease areas where inflammatory priming may matter. - The company is also positioning the publication as a tool for attracting researchers and potential partners to specific indications. - Future work will need to determine which diseases, biomarkers and patient subgroups are most likely to show benefit.

The bottom line: - Palisades Therapeutics is using its new Perspective to argue that a shared inflammatory mechanism may connect several chronic diseases, and that glucocorticoid receptor modulation deserves broader testing as a targeted upstream strategy.